DUBLIN--(BUSINESS WIRE)--The "Global Interventional Cardiology Market (2014-2022)" report has been added to ResearchAndMarkets.com's offering.
The global interventional cardiology market is likely to grow at a CAGR of 6.9% (2017-2022) resulting in a global revenue of USD 21.88 billion by 2022.
The interventional cardiology market is poised to grow at a steady rate over the forecast period given that the use of interventional cardiology devices has increased significantly. Public as well as private sector hospitals have started using interventional cardiology products.
The stents as well as catheters segment are expected to grow at a significant rate. Among the various applications, the angioplasty segment has held the maximum share of the market and is expected to grow at a considerable rate over the forecast period. Valvuloplasty is the other application area that is likely to gain momentum, especially in pediatric interventional cardiology.
Key growth factors
The development of advanced minimally invasive procedures and increase in adoption of the same in interventional cardiology is likely to drive the global market in the future. Moreover, the development of hybrid procedures is another trend that is likely to gain acceptance across the industry in the coming years.
Increasing number of people with heart diseases around the world, rise in population, and growth of pediatric heart diseases are some of the other factors that are expected to push the progress of the overall interventional cardiology market in a growth trajectory.
Threats and key players
Despite the optimistic growth forecast of the interventional cardiology market, some restraining factors must be taken into consideration while analyzing the overall market scenario. Post-procedural complexities such as blood clotting or thrombosis, uneven drug release, and varying rates of degradation are some of the factors that may hinder the growth of the market.
Moreover, the market scenario of interventional cardiology is very dynamic. The intensity of competition among companies is reasonably high. Price cuts offered by small and medium players on their devices compel established players to reduce their profit margins, thereby leading to an inhibition of the research and development efforts owing to lack of funds. This may become a strong restraining factor in the extended long term.
Key Topics Covered:
Chapter 1: Executive Summary
Chapter 2: Introduction - Interventional Cardiology Market
Chapter 3: Timeline - Interventional Cardiology Market
Chapter 4: Interventional Cardiology Market Overview
Chapter 5: Regional Overview
Chapter 6: Segmentation Overview-By Type
Chapter 7: Segmentation Overview-By Application
Chapter 8: Company Profiles
Chapter 9: Conclusion
Chapter 10: Appendix
- Abbott Laboratories, S.A.
- B. Braun Melsungen AG
- Boston Scientific Corporation
- C. R. Bard, Inc.
- Edwards Lifesciences Corporation
- Johnson & Johnson Pvt. Ltd.
- Livanova, PLC.
- Medtronic PLC
- Microport Medical Apparatus (Shanghai) Co. Ltd.
- Teleflex Incorporated
For more information about this report visit https://www.researchandmarkets.com/research/khds3j/global?w=4